Biocon’s arm executes debt facility agreement

22 Nov 2022 Evaluate

Biocon’s subsidiary -- Biocon Biologics (BBL) and its subsidiaries have executed a debt facility agreement which is classified as a Sustainability-linked Loan (SLL) amounting to $1.2 billion on November 20, 2022, the proceeds of which shall be used for funding the acquisition of Viatris Inc.’s biosimilars business and acquisition related expenses.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

376.00 -1.55 (-0.41%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×